|Day's range||81.60 - 81.60|
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share...
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cogniti
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what...
Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline.
Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal,2 and ultra-rare genetic form of ALS3-4 with approximately 330 people in the U.S. living with the disease5 CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 10
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?